We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always looking at the latest trends in value, growth, and momentum to find strong picks.
Looking at the history of these trends, perhaps none is more beloved than value investing. This strategy simply looks to identify companies that are being undervalued by the broader market. Value investors rely on traditional forms of analysis on key valuation metrics to find stocks that they believe are undervalued, leaving room for profits.
On top of the Zacks Rank, investors can also look at our innovative Style Scores system to find stocks with specific traits. For example, value investors will want to focus on the "Value" category. Stocks with high Zacks Ranks and "A" grades for Value will be some of the highest-quality value stocks on the market today.
Envista (NVST - Free Report) is a stock many investors are watching right now. NVST is currently sporting a Zacks Rank #2 (Buy), as well as a Value grade of A.
Investors should also note that NVST holds a PEG ratio of 1.05. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. NVST's PEG compares to its industry's average PEG of 1.92. Over the past 52 weeks, NVST's PEG has been as high as 2.68 and as low as 0.90, with a median of 1.13.
Another notable valuation metric for NVST is its P/B ratio of 1.11. The P/B is a method of comparing a stock's market value to its book value, which is defined as total assets minus total liabilities. This company's current P/B looks solid when compared to its industry's average P/B of 2.35. Over the past year, NVST's P/B has been as high as 1.30 and as low as 0.82, with a median of 1.08.
Value investors also use the P/S ratio. The P/S ratio is calculated as price divided by sales. This is a preferred metric because revenue can't really be manipulated, so sales are often a truer performance indicator. NVST has a P/S ratio of 1.33. This compares to its industry's average P/S of 1.63.
If you're looking for another solid Medical - Products value stock, take a look at Phibro Animal Health (PAHC - Free Report) . PAHC is a Zacks Rank of #2 (Buy) stock with a Value score of A.
Shares of Phibro Animal Health are currently trading at a forward earnings multiple of 15.37 and a PEG ratio of 1.20 compared to its industry's P/E and PEG ratios of 16.19 and 1.92, respectively.
PAHC's Forward P/E has been as high as 16.56 and as low as 7.98, with a median of 12.28. During the same time period, its PEG ratio has been as high as 1.74, as low as 0.30, with a median of 0.50.
Furthermore, Phibro Animal Health holds a P/B ratio of 5.66 and its industry's price-to-book ratio is 2.35. PAHC's P/B has been as high as 5.85, as low as 2.52, with a median of 3.67 over the past 12 months.
These are just a handful of the figures considered in Envista and Phibro Animal Health's great Value grade. Still, they help show that the stock is likely being undervalued at the moment. Add this to the strength of its earnings outlook, and we can clearly see that NVST and PAHC is an impressive value stock right now.
View the Zacks #1 Rank List
Image: Bigstock
Should Value Investors Buy Envista (NVST) Stock?
The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always looking at the latest trends in value, growth, and momentum to find strong picks.
Looking at the history of these trends, perhaps none is more beloved than value investing. This strategy simply looks to identify companies that are being undervalued by the broader market. Value investors rely on traditional forms of analysis on key valuation metrics to find stocks that they believe are undervalued, leaving room for profits.
On top of the Zacks Rank, investors can also look at our innovative Style Scores system to find stocks with specific traits. For example, value investors will want to focus on the "Value" category. Stocks with high Zacks Ranks and "A" grades for Value will be some of the highest-quality value stocks on the market today.
Envista (NVST - Free Report) is a stock many investors are watching right now. NVST is currently sporting a Zacks Rank #2 (Buy), as well as a Value grade of A.
Investors should also note that NVST holds a PEG ratio of 1.05. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. NVST's PEG compares to its industry's average PEG of 1.92. Over the past 52 weeks, NVST's PEG has been as high as 2.68 and as low as 0.90, with a median of 1.13.
Another notable valuation metric for NVST is its P/B ratio of 1.11. The P/B is a method of comparing a stock's market value to its book value, which is defined as total assets minus total liabilities. This company's current P/B looks solid when compared to its industry's average P/B of 2.35. Over the past year, NVST's P/B has been as high as 1.30 and as low as 0.82, with a median of 1.08.
Value investors also use the P/S ratio. The P/S ratio is calculated as price divided by sales. This is a preferred metric because revenue can't really be manipulated, so sales are often a truer performance indicator. NVST has a P/S ratio of 1.33. This compares to its industry's average P/S of 1.63.
If you're looking for another solid Medical - Products value stock, take a look at Phibro Animal Health (PAHC - Free Report) . PAHC is a Zacks Rank of #2 (Buy) stock with a Value score of A.
Shares of Phibro Animal Health are currently trading at a forward earnings multiple of 15.37 and a PEG ratio of 1.20 compared to its industry's P/E and PEG ratios of 16.19 and 1.92, respectively.
PAHC's Forward P/E has been as high as 16.56 and as low as 7.98, with a median of 12.28. During the same time period, its PEG ratio has been as high as 1.74, as low as 0.30, with a median of 0.50.
Furthermore, Phibro Animal Health holds a P/B ratio of 5.66 and its industry's price-to-book ratio is 2.35. PAHC's P/B has been as high as 5.85, as low as 2.52, with a median of 3.67 over the past 12 months.
These are just a handful of the figures considered in Envista and Phibro Animal Health's great Value grade. Still, they help show that the stock is likely being undervalued at the moment. Add this to the strength of its earnings outlook, and we can clearly see that NVST and PAHC is an impressive value stock right now.